Cardiovascular Toxicities of Androgen Deprivation Therapy

被引:39
作者
Challa, Azariyas A. [1 ]
Calaway, Adam Christopher [2 ]
Cullen, Jennifer [3 ]
Garcia, Jorge [4 ]
Desai, Nihar [5 ,6 ]
Weintraub, Neal L. [7 ,8 ]
Deswal, Anita [9 ]
Kutty, Shelby [10 ,11 ]
Vallakati, Ajay [1 ]
Addison, Daniel [1 ]
Baliga, Ragavendra [1 ]
Campbell, Courtney M. [1 ]
Guha, Avirup [1 ,12 ]
机构
[1] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Cardiooncol Program,Div Cardiovasc Med, Columbus, OH 43210 USA
[2] Case Western Reserve Univ, Sch Med, Dept Urol, Univ Hosp Cleveland Med Ctr, Cleveland, OH USA
[3] Case Comprehens Canc Ctr, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA
[4] Case Western Reserve Univ, Sch Med, Univ Hosp Seidman Canc Ctr, Div Solid Tumor Oncol, Cleveland, OH USA
[5] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA
[6] Ctr Outcomes Res & Evaluat, New Haven, CT USA
[7] Augusta Univ, Vasc Biol Ctr, August, GA USA
[8] Augusta Univ, Med Coll Georgia, Dept Med, August, GA USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA
[10] Johns Hopkins Univ Hosp, Helen B Taussig Heart Ctr, Baltimore, MD 21287 USA
[11] Johns Hopkins Univ, Baltimore, MD USA
[12] UH Cleveland Med Ctr, Harrington Heart & Vasc Inst, Cleveland, OH 44106 USA
关键词
Prostate cancer; Cardiovascular disease; Mortality; Side effects; Cardiotoxicity; Hormones; Prevention; METASTATIC PROSTATE-CANCER; OPEN-LABEL; SUPPRESSION THERAPY; HORMONE ANTAGONIST; RISK-FACTOR; MEN; TESTOSTERONE; DISEASE; RECEPTOR; METAANALYSIS;
D O I
10.1007/s11864-021-00846-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Opinion statement Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer. Androgen deprivation therapy, the cornerstone of prostate cancer treatment, has been associated with adverse cardiovascular events. Emerging data supports decreased cardiovascular risk of gonadotropin releasing hormone (GnRH) antagonists compared to agonists. Ongoing clinical trials are assessing the relative safety of different modalities of androgen deprivation therapy. Racial disparities in cardiovascular outcomes in prostate cancer patients are starting to be explored. An intriguing inquiry connects androgen deprivation therapy with reduced risk of COVID-19 infection susceptibility and severity. Recognition of the cardiotoxicity of androgen deprivation therapy and aggressive risk factor modification are crucial for optimal patient care.
引用
收藏
页数:20
相关论文
共 104 条
[61]   Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease [J].
Margel, David ;
Peer, Avivit ;
Ber, Yaara ;
Shavit-Grievink, Liat ;
Tabachnik, Tzlil ;
Sela, Sivan ;
Witberg, Guy ;
Baniel, Jack ;
Kedar, Daniel ;
Duivenvoorden, Wilhelmina C. M. ;
Rosenbaum, Eli ;
Pinthus, Jehonathan H. .
JOURNAL OF UROLOGY, 2019, 202 (06) :1199-1207
[62]   A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer [J].
McLeod, D ;
Zinner, N ;
Tomera, K ;
Gleason, D ;
Fotheringham, N ;
Campion, M ;
Garnick, MB .
UROLOGY, 2001, 58 (05) :756-761
[63]   Cardiovascular risk patients under androgen deprivation therapy. Lower risk with GnRH antagonists compared to LHRH agonists? [J].
Merseburger, Axel S. ;
Sedding, Daniel ;
Hueter, Kai .
UROLOGE, 2016, 55 (02) :218-225
[64]   Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N=4532) [J].
Montopoli, M. ;
Zumerle, S. ;
Vettor, R. ;
Rugge, M. ;
Zorzi, M. ;
Catapano, C., V ;
Carbone, G. M. ;
Cavalli, A. ;
Pagano, F. ;
Ragazzi, E. ;
Prayer-Galetti, T. ;
Alimonti, A. .
ANNALS OF ONCOLOGY, 2020, 31 (08) :1040-1045
[65]   Influence of Age on Incident Diabetes and Cardiovascular Disease in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy [J].
Morgans, Alicia K. ;
Fan, Kang-Hsien ;
Koyama, Tatsuki ;
Albertsen, Peter C. ;
Goodman, Michael ;
Hamilton, Ann S. ;
Hoffman, Richard M. ;
Stanford, Janet L. ;
Stroup, Antoinette M. ;
Resnick, Matthew J. ;
Barocas, Daniel A. ;
Penson, David F. .
JOURNAL OF UROLOGY, 2015, 193 (04) :1226-1231
[66]   Neoadjuvant Hormonal Therapy Use and the Risk of Death in Men with Prostate Cancer Treated with Brachytherapy Who Have No or at Least a Single Risk Factor for Coronary Artery Disease [J].
Nanda, Akash ;
Chen, Ming-Hui ;
Moran, Brian J. ;
Braccioforte, Michelle H. ;
Dosoretz, Daniel ;
Salenius, Sharon ;
Katin, Michael ;
Ross, Rudi ;
D'Amico, Anthony V. .
EUROPEAN UROLOGY, 2014, 65 (01) :177-185
[67]   INFLUENCE OF ANDROGEN DEPRIVATION THERAPY ON ALL-CAUSE MORTALITY IN MEN WITH HIGH-RISK PROSTATE CANCER AND A HISTORY OF CONGESTIVE HEART FAILURE OR MYOCARDIAL INFARCTION [J].
Nguyen, Paul L. ;
Chen, Ming-Hui ;
Beckman, Joshua A. ;
Beard, Clair J. ;
Martin, Neil E. ;
Choueiri, Toni K. ;
Hu, Jim C. ;
Hoffman, Karen E. ;
Dosoretz, Daniel E. ;
Moran, Brian J. ;
Salenius, Sharon A. ;
Braccioforte, Michelle H. ;
Kantoff, Philip W. ;
D'Amico, Anthony V. ;
Ennis, Ronald D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (04) :1411-1416
[68]   Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer A Meta-analysis of Randomized Trials [J].
Nguyen, Paul L. ;
Je, Youjin ;
Schutz, Fabio A. B. ;
Hoffman, Karen E. ;
Hu, Jim C. ;
Parekh, Arti ;
Beckman, Joshua A. ;
Choueiri, Toni K. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (21) :2359-2366
[69]   Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer [J].
O'Farrell, Sean ;
Garmo, Hans ;
Holmberg, Lars ;
Adolfsson, Jan ;
Stattin, Par ;
Van Hemelrijck, Mieke .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (11) :1243-+
[70]   The molecular and cellular origin of human prostate cancer [J].
Packer, John R. ;
Maitland, Norman J. .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2016, 1863 (06) :1238-1260